TRT and Sperm Count: Understanding the Impact on Male Fertility

TRT and Sperm Count: What You Need to Know Last Updated: May 2024

Exogenous testosterone replacement therapy (TRT) profoundly impacts male fertility, with studies indicating that approximately 60% of men will develop azoospermia (absence of sperm) and the remainder will experience severe oligozoospermia (sperm count below 5 million/mL) within months of initiating therapy. This significant suppression of spermatogenesis is a critical consideration for men seeking TRT who also wish to preserve or restore their fertility.

The Core Mechanism: How TRT Affects Fertility

The human reproductive system operates on a delicate feedback loop known as the Hypothalamic-Pituitary-Gonadal (HPG) axis.

1. Hypothalamus: Releases Gonadotropin-Releasing Hormone (GnRH).
2. Pituitary Gland: Stimulated by GnRH to release Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).
3. Testes:
   • LH stimulates Leydig cells to produce testosterone.
   • FSH, alongside adequate intratesticular testosterone (ITT) produced by Leydig cells, is essential for Sertoli cells to support spermatogenesis.

When exogenous testosterone, such as testosterone cypionate or enanthate (typically administered at 100–200mg per week), is introduced into the body, it signals to the hypothalamus and pituitary that sufficient testosterone is present. This triggers a negative feedback loop, causing the hypothalamus to reduce GnRH production, which in turn diminishes LH and FSH release from the pituitary.

The consequences for fertility are direct:

• Reduced LH leads to decreased stimulation of Leydig cells, lowering the testes’ natural testosterone production.
• Reduced FSH and insufficient ITT directly impair the Sertoli cells’ ability to support sperm development.

This cascade effectively “shuts down” the testes’ ability to produce sperm, a state often referred to as gonadal atrophy or testicular suppression.

Quantifying Spermatogenesis Suppression

The degree and speed of spermatogenesis suppression vary but are consistently significant. Research demonstrates that within 6 to 12 weeks of starting exogenous testosterone, most men will exhibit severely compromised sperm parameters. A review published in Translational Andrology and Urology (Shabsigh et al., 2018) highlights that “exogenous testosterone therapy leads to suppression of spermatogenesis in almost all men, with azoospermia (absence of sperm) developing in about 60% and severe oligozoospermia (sperm count <5 million/mL) in the remainder.” This means that traditional TRT protocols, while effective for resolving symptoms of hypogonadism and optimizing total testosterone levels (e.g., to 500–1000 ng/dL), are fundamentally contraceptive. The Endocrine Society’s 2018 Clinical Practice Guidelines on Testosterone Therapy in Men with Hypogonadism even states: “Testosterone therapy is contraindicated in men desiring fertility.”

Strategies for Fertility Preservation on TRT

For men who require TRT but still desire to father children, several strategies can mitigate or bypass the suppressive effects on spermatogenesis.

Sperm Cryopreservation (Sperm Banking)

The most direct and foolproof method to preserve fertility before initiating TRT is sperm banking. This involves collecting and freezing sperm samples, which can be stored indefinitely and used for future assisted reproductive technologies (ART) such as in vitro fertilization (IVF). This option provides certainty and removes the immediate pressure to maintain fertility while on TRT.

HCG (Human Chorionic Gonadotropin) Concomitant with TRT

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone that structurally and functionally mimics LH. When administered alongside exogenous testosterone, HCG directly stimulates the Leydig cells in the testes to produce endogenous testosterone. This action helps maintain intratesticular testosterone (ITT) levels, which are crucial for spermatogenesis, and can prevent or reduce testicular atrophy.

• Mechanism: Acts as an LH analog, bypassing the pituitary suppression caused by exogenous testosterone.
• Dosages: Typically administered at 500–1000 IU 2–3 times per week, injected subcutaneously or intramuscularly.
• Effectiveness: While HCG can significantly preserve testicular function and, in many cases, maintain sufficient sperm production for fertility, it does not guarantee full spermatogenesis for all men. Its efficacy can vary, and regular semen analysis is recommended to monitor its impact.

Enclomiphene Citrate: A Fertility-Sparing Alternative

Enclomiphene citrate is a selective estrogen receptor modulator (SERM) that offers a unique approach to managing low testosterone while preserving fertility. Unlike traditional TRT, which replaces testosterone exogenously, enclomiphene works by blocking estrogen’s negative feedback at the hypothalamus and pituitary gland. This leads to an increase in GnRH secretion, which in turn elevates LH and FSH production.

• Mechanism: By increasing endogenous LH and FSH, enclomiphene stimulates the testes to produce more natural testosterone and supports spermatogenesis, without introducing exogenous hormones. This makes it a “restorative” approach rather than a “replacement” approach.
• Dosages: Commonly prescribed at 25 mg daily or every other day.
• Effectiveness: Clinical trials, such as the study by Wiehle et